AstraZeneca doubles down on Chinese business through a new drug development joint venture with a state-backed private equity firm.
DiA Imaging Analysis has inked a deal with GE Healthcare to develop automated imaging analysis technology.
When payers and biopharma fight over pricing, patients with rare diseases can suffer. See how Real World Evidence and value-based contracts can help.
Ionis Pharmaceuticals has signed the rights to a second antisense drug over to Janssen for a fee of $5 million.
Evelo Biosciences has just forged closer ties with a heavyweight academic partner for its monoclonal microbials R&D, which envisages using bacteria to…
Bay Area drug discovery company Verge Genomics has formed industry and academic alliances in neuro disorders.
The expansion of the deal gives the Roche subsidiary the chance to use Arvinas’ protein degradation technology against additional disease targets.
Loxo predicts the deal for its tropomyosin receptor kinase inhibitor franchise will generate $1 billion over the next few years.
The Parker Institute for Cancer Immunotherapy is sponsoring the trial, which will take place at the MD Anderson Cancer Center.
The pact tasks CureVac with developing Cas9 mRNA constructs for use in three in vivo gene-editing liver disease programs.
Aquila BioMedical signed an extended contract with Macrophage Pharma to support its preclinical immuno-oncology programs.